{"DataElement":{"publicId":"7648234","version":"2","preferredName":"Best Overall Response Sponsor Defined Code","preferredDefinition":"A character or string that represents the short code for the best overall disease response as defined by the sponsor.","longName":"BESTRESP_SPD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6927206","version":"1","preferredName":"Disease Response Domain Lesion Best Overall Response","preferredDefinition":"A domain for disease response evaluations._A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._The most clinically favorable response recorded from the start of the study treatment until the end of treatment.","longName":"6608777v1.0:6927204v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6608777","version":"1","preferredName":"Disease Response Domain","preferredDefinition":"A domain for disease response evaluations.","longName":"C107097","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response Domain","conceptCode":"C107097","definition":"A domain for disease response evaluations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6DD03A-0CB9-71AE-E053-F662850AB42C","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"ONEDATA","dateModified":"2019-01-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6927204","version":"1","preferredName":"Lesion Best Overall Response","preferredDefinition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.:The most clinically favorable response recorded from the start of the study treatment until the end of treatment.","longName":"C3824:C94536","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Best Overall Response","conceptCode":"C94536","definition":"The most clinically favorable response recorded from the start of the study treatment until the end of treatment.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"924EB6ED-1271-5B25-E053-F662850A7121","latestVersionIndicator":"Yes","beginDate":"2019-09-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-11","modifiedBy":"ONEDATA","dateModified":"2019-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"924EB6ED-1282-5B25-E053-F662850A7121","latestVersionIndicator":"Yes","beginDate":"2019-09-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-11","modifiedBy":"COOPERM","dateModified":"2020-06-04","changeDescription":"Created for CDSIC aligned NCI Standard CRFs. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7648232","version":"2","preferredName":"Best Overall Response Clinical Study Sponsor Defined Code","preferredDefinition":"The most clinically favorable response recorded from the start of the study treatment until the end of treatment._An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]_Clearly characterized or delimited._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"BESTRESP_SPD","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"UN","valueDescription":"Unknown","ValueMeaning":{"publicId":"2960664","version":"1","preferredName":"Unknown","longName":"2960664","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78485FBD-4C65-D67B-E040-BB89AD432E0E","latestVersionIndicator":"Yes","beginDate":"2009-11-13","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-11-13","modifiedBy":"KUMMEROA","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB91-7B1F-E063-731AD00AE1F1","beginDate":"2021-04-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2023-09-20","modifiedBy":"ONEDATA","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"NA","valueDescription":"NOT ASSESSED","ValueMeaning":{"publicId":"2559594","version":"1","preferredName":"NOT ASSESSED","longName":"2559594","preferredDefinition":"Indicates that an assessment was not performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Assessed","conceptCode":"C139527","definition":"Indicates that an assessment was not performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB92-7B1F-E063-731AD00AE1F1","beginDate":"2021-04-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2023-09-20","modifiedBy":"ONEDATA","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"MR","valueDescription":"Minor Response","ValueMeaning":{"publicId":"5607583","version":"1","preferredName":"Minor Response","longName":"5607583","preferredDefinition":"A finding indicating that there is an improvement in the measures of disease burden, meeting a predetermined threshold, but not meeting partial response criteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minimal Response","conceptCode":"C123598","definition":"A finding indicating that there is an improvement in the measures of disease burden, meeting a predetermined threshold, but not meeting partial response criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44053298-D162-7592-E053-F662850AB82F","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"SOKKERL","dateModified":"2023-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB93-7B1F-E063-731AD00AE1F1","beginDate":"2021-04-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2023-09-20","modifiedBy":"ONEDATA","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"CR","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3951936","version":"1","preferredName":"Complete Remission","longName":"3951936v1.00","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB155E17-C5DA-CEC3-E040-BB89AD4342C2","latestVersionIndicator":"Yes","beginDate":"2013-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-13","modifiedBy":"SOKKERL","dateModified":"2023-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB94-7B1F-E063-731AD00AE1F1","beginDate":"2017-08-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2023-09-20","modifiedBy":"ONEDATA","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"NE","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3855538","version":"1","preferredName":"Unevaluable","longName":"3855538","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F3FD8B-328D-C859-E040-BB89AD43580F","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB95-7B1F-E063-731AD00AE1F1","beginDate":"2017-08-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2023-09-20","modifiedBy":"ONEDATA","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"PD","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"3284666","version":"1","preferredName":"Progressive Disease","longName":"3284666v1.00","preferredDefinition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD9FC7D6-531D-BE97-E040-BB89AD437875","latestVersionIndicator":"Yes","beginDate":"2011-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-23","modifiedBy":"MMADDINENI","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":"2023.5.17 Alt VM added per ticket request CADSR0002435. ak \r\n2023.3.15 Per LS at COG Protocol defined progressive disease (should have been added as a VM Alt Name for PV 3284666). ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB96-7B1F-E063-731AD00AE1F1","beginDate":"2017-08-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2023-09-20","modifiedBy":"ONEDATA","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"PR","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"3951935","version":"1","preferredName":"Partial Remission","longName":"3951935","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB155E17-C5B7-CEC3-E040-BB89AD4342C2","latestVersionIndicator":"Yes","beginDate":"2013-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB97-7B1F-E063-731AD00AE1F1","beginDate":"2017-08-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2023-09-20","modifiedBy":"ONEDATA","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"SD","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"3859302","version":"1","preferredName":"Stable Disease","longName":"3859302","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E461EC27-2518-B912-E040-BB89AD43049F","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-08-20","modifiedBy":"SOKKERL","dateModified":"2023-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB98-7B1F-E063-731AD00AE1F1","beginDate":"2013-08-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2023-09-20","modifiedBy":"ONEDATA","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"TE","valueDescription":"Too Early","ValueMeaning":{"publicId":"2857269","version":"1","preferredName":"Too Early","longName":"2857269","preferredDefinition":"At a point before the usual, expected, or specified time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Too Early","conceptCode":"C133441","definition":"At a point before the usual, expected, or specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"663026CD-D68F-9954-E040-BB89AD437359","latestVersionIndicator":"Yes","beginDate":"2009-03-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added concept annotation. mc 4/12/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB99-7B1F-E063-731AD00AE1F1","beginDate":"2021-04-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2023-09-20","modifiedBy":"ONEDATA","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"cPR","valueDescription":null,"ValueMeaning":{"publicId":"6674544","version":"1","preferredName":"Clinical Partial Response","longName":"6674544v1.00","preferredDefinition":"A decrease in the size and the extent of tissue involvement by cancer, based on physical exam, such as palpation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Partial Response","conceptCode":"C123576","definition":"A decrease in the size and the extent of tissue involvement by cancer, based on physical exam, such as palpation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-E08C-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"MMADDINENI","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB9A-7B1F-E063-731AD00AE1F1","beginDate":"2023-09-13","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-20","modifiedBy":"MMADDINENI","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"CRMRD-","valueDescription":null,"ValueMeaning":{"publicId":"14476344","version":"1","preferredName":"Complete Response without Minimal Residual Disease","longName":"14476344v1.00","preferredDefinition":"Complete response with no detectable signs of disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Response without Minimal Residual Disease","conceptCode":"C201494","definition":"Complete response with no detectable signs of disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05569855-17BF-472B-E063-731AD00AEB8C","latestVersionIndicator":"Yes","beginDate":"2023-09-14","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-14","modifiedBy":"MMADDINENI","dateModified":"2023-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB9B-7B1F-E063-731AD00AE1F1","beginDate":"2023-09-14","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-20","modifiedBy":"MMADDINENI","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"HI","valueDescription":null,"ValueMeaning":{"publicId":"14476604","version":"1","preferredName":"Hematologic Improvement","longName":"14476604v1.00","preferredDefinition":"An improvement in one or more hematologic cell counts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Improvement","conceptCode":"C201498","definition":"An improvement in one or more hematologic cell counts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"056B69D1-42F1-0A2F-E063-731AD00A9150","latestVersionIndicator":"Yes","beginDate":"2023-09-15","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-15","modifiedBy":"MMADDINENI","dateModified":"2023-09-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB9C-7B1F-E063-731AD00AE1F1","beginDate":"2023-09-15","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-20","modifiedBy":"MMADDINENI","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"CRi","valueDescription":null,"ValueMeaning":{"publicId":"6674540","version":"1","preferredName":"Complete Response with Incomplete Bone Marrow Recovery","longName":"6674540","preferredDefinition":"The disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Response with Incomplete Bone Marrow Recovery","conceptCode":"C103385","definition":"The disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-E035-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"MMADDINENI","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":"2023.3.22 Alt VM added per ticket request CADSR0002191. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB9D-7B1F-E063-731AD00AE1F1","beginDate":"2023-09-13","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-20","modifiedBy":"MMADDINENI","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"MORPHOLOGIC LEUKEMIA-FREE STATE","valueDescription":null,"ValueMeaning":{"publicId":"2581112","version":"1","preferredName":"Morphologic Leukemia - Free State","longName":"2581112","preferredDefinition":"The disappearance of all cells with morphologic characteristics of leukemia, accompanied by bone marrow recovery, in response to treatment. Hematologic recovery is not required. Leukemia free state can be a hypocellular marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Leukemia-Free State","conceptCode":"C123597","definition":"The disappearance of all cells with morphologic characteristics of leukemia, accompanied by bone marrow recovery, in response to treatment. Hematologic recovery is not required. Leukemia free state can be a hypocellular marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-09E5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"COOPERM","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB9E-7B1F-E063-731AD00AE1F1","beginDate":"2023-09-13","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-20","modifiedBy":"MMADDINENI","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"TREATMENT FAILURE","valueDescription":null,"ValueMeaning":{"publicId":"2578570","version":"1","preferredName":"Lack of Efficacy","longName":"2578570","preferredDefinition":"The lack of expected or desired effect related to a therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lack of Efficacy","conceptCode":"C48226","definition":"The lack of expected or desired effect related to a therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FFF7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":"2023.3.22 Alt VM added per ticket request CADSR0002191. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BB9F-7B1F-E063-731AD00AE1F1","beginDate":"2023-09-13","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-20","modifiedBy":"MMADDINENI","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"MRD","valueDescription":null,"ValueMeaning":{"publicId":"3664073","version":"1","preferredName":"Minimal Residual Disease","longName":"3664073","preferredDefinition":"remainder of a tumor or a neoplasm/cancer after primary, potentially curative therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measurable Residual Disease","conceptCode":"C3896","definition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D44D9BFE-CCF9-ABE8-E040-BB89AD431D2C","latestVersionIndicator":"Yes","beginDate":"2013-01-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-27","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BBA0-7B1F-E063-731AD00AE1F1","beginDate":"2023-09-13","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-20","modifiedBy":"MMADDINENI","dateModified":"2023-09-20","deletedIndicator":"No"},{"value":"PRD","valueDescription":null,"ValueMeaning":{"publicId":"14476219","version":"1","preferredName":"Primary Refractory","longName":"14476219v1.00","preferredDefinition":"Disease status just prior to the start of the preparative regimen for hematopoietic stem cell transplantation (HSCT): Primary refractory refers to never achieving a complete remission (CR) from any therapy and also not being in partial remission (PR) at the time of the last evaluation prior to HSCT.  PR could have been achieved at some point, but the recipient is no longer in PR.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Refractory","conceptCode":"C70604","definition":"Disease status just prior to the start of the preparative regimen for hematopoietic stem cell transplantation (HSCT): Primary refractory refers to never achieving a complete remission (CR) from any therapy and also not being in partial remission (PR) at the time of the last evaluation prior to HSCT.  PR could have been achieved at some point, but the recipient is no longer in PR.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"054440FE-A1D1-0948-E063-731AD00A1CF6","latestVersionIndicator":"Yes","beginDate":"2023-09-13","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-13","modifiedBy":"MMADDINENI","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05CC0398-BBA1-7B1F-E063-731AD00AE1F1","beginDate":"2023-09-13","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-20","modifiedBy":"MMADDINENI","dateModified":"2023-09-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7648231","version":"1","preferredName":"Best Overall Response Clinical Study Sponsor Defined Code","preferredDefinition":"The most clinically favorable response recorded from the start of the study treatment until the end of treatment.:An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]:Clearly characterized or delimited.:A symbol or combination of symbols which is assigned to the members of a collection.","longName":"C94536:C70793:C165683:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best Overall Response","conceptCode":"C94536","definition":"The most clinically favorable response recorded from the start of the study treatment until the end of treatment.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Clinical Study Sponsor","conceptCode":"C70793","definition":"An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Defined","conceptCode":"C165683","definition":"Clearly characterized or delimited.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C10C1B12-A3B2-2162-E053-4EBD850AB67E","latestVersionIndicator":"Yes","beginDate":"2021-04-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-04-28","modifiedBy":"ONEDATA","dateModified":"2021-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05CC039E-E208-7B1B-E063-731AD00A87FB","latestVersionIndicator":"Yes","beginDate":"2021-04-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-09-20","modifiedBy":"SOKKERL","dateModified":"2023-09-20","changeDescription":"CDISC NSV 10329; TL.","administrativeNotes":"9/20/23- versioned to 2.0 to increase max VD.LS","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Best Overall Response","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Response Assessment","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05CC2CFD-1613-06EE-E063-731AD00AA31B","latestVersionIndicator":"Yes","beginDate":"2021-04-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-09-20","modifiedBy":"SOKKERL","dateModified":"2023-09-20","changeDescription":"10329 CDISC NSV; TL.","administrativeNotes":"9/20/23 versioned to 2.0 to increase max VD length. LS","unresolvedIssues":null,"deletedIndicator":"No"}}